The market reacts to news about "Farmsintez's" agreement with LDA Capital excessively positively

Growth of papers is caused by signed SLDA Capital the agreement according to which "Farmsintez" will receive to 800 million rubles. Thus the agreement, according to available information, does not provide a special-purpose character of use of means: company can napravity on clinical trials, production generics, vaccines and a drugiyenapravleniye. In exchange for etoLDA Capital acquires the right for repayment to 19,9% of actions of companies on the closed subscription...